Archives of Toxicology,
Journal Year:
2021,
Volume and Issue:
95(7), P. 2279 - 2297
Published: May 18, 2021
Over
the
last
decade,
important
clinical
benefits
have
been
achieved
in
cancer
patients
by
using
drug-targeting
strategies.
Nevertheless,
drug
resistance
is
still
a
major
problem
most
therapies.
Epithelial-mesenchymal
plasticity
(EMP)
and
tumour
microenvironment
described
as
limiting
factors
for
effective
treatment
many
types.
Moreover,
epithelial-to-mesenchymal
transition
(EMT)
has
also
associated
with
therapy
different
preclinical
models,
although
limited
evidence
obtained
from
studies
samples.
In
this
review,
we
particularly
deepen
into
mechanisms
of
which
intermediate
epithelial/mesenchymal
(E/M)
states
its
interconnection
to
influence
resistance.
We
describe
how
use
bioinformatics
pharmacogenomics
will
help
figure
out
biological
impact
EMT
on
develop
novel
pharmacological
approaches
future.
Cell,
Journal Year:
2021,
Volume and Issue:
184(9), P. 2471 - 2486.e20
Published: April 1, 2021
Metastasis
has
been
considered
as
the
terminal
step
of
tumor
progression.
However,
recent
genomic
studies
suggest
that
many
metastases
are
initiated
by
further
spread
other
metastases.
Nevertheless,
corresponding
pre-clinical
models
lacking,
and
underlying
mechanisms
elusive.
Using
several
approaches,
including
parabiosis
an
evolving
barcode
system,
we
demonstrated
bone
microenvironment
facilitates
breast
prostate
cancer
cells
to
metastasize
establish
multi-organ
secondary
We
uncovered
this
metastasis-promoting
effect
is
driven
epigenetic
reprogramming
confers
stem
cell-like
properties
on
disseminated
from
lesions.
Furthermore,
discovered
enhanced
EZH2
activity
mediates
increased
stemness
metastasis
capacity.
The
same
findings
also
apply
single
cell-derived
populations,
indicating
distinct
clonal
selection.
Taken
together,
our
work
revealed
unappreciated
role
in
evolution
elucidated
epigenomic
process
driving
terminal-stage,
Neuro-Oncology,
Journal Year:
2021,
Volume and Issue:
24(5), P. 669 - 682
Published: Nov. 23, 2021
Phenotypic
plasticity
has
emerged
as
a
major
contributor
to
intra-tumoral
heterogeneity
and
treatment
resistance
in
cancer.
Increasing
evidence
shows
that
glioblastoma
(GBM)
cells
display
prominent
intrinsic
reversibly
adapt
dynamic
microenvironmental
conditions.
Limited
genetic
evolution
at
recurrence
further
suggests
mechanisms
also
largely
operate
the
phenotypic
level.
Here
we
review
recent
literature
underpinning
role
of
GBM
creating
gradients
heterogeneous
including
those
carry
cancer
stem
cell
(CSC)
properties.
A
historical
perspective
from
hierarchical
nonhierarchical
concept
CSCs
towards
appreciation
is
provided.
Cellular
states
interact
dynamically
with
each
other
surrounding
brain
shape
flexible
tumor
ecosystem,
which
enables
swift
adaptation
external
pressure
treatment.
We
present
key
components
regulating
equilibrium
states,
genetic,
epigenetic,
factors.
discuss
context
resistance,
where
variable
balance
between
preexisting
resistant
adaptive
persisters
leads
reversible
upon
Innovative
efforts
targeting
regulators
state
transitions
treatment-resistant
are
needed
restrict
capacities
GBM.
Proceedings of the National Academy of Sciences,
Journal Year:
2021,
Volume and Issue:
118(8)
Published: Feb. 17, 2021
Significance
Cartilage
is
essential
in
vertebrate
development
and
adulthood.
growth
plates
ensure
skeletal
until
closing
at
puberty,
articular
cartilage
ensures
lifelong
structural
functional
integrity
of
joints.
Chondrocytes
build
development,
governed
by
the
transcription
factor
SOX9.
Using
mouse
models
transcriptome
profiling
approaches,
we
show
here
that
SOX9
also
has
key
roles
to
maintain
open
postnatally
protect
adult
from
osteoarthritic
degradation.
In
particular,
safeguards
lineage
fate
chondrocytes
preventing
their
dedifferentiation
into
skeletogenic
mesenchymal
progenitors
followed
redifferentiation
osteoblasts.
These
findings
provide
insights
cellular
plasticity
its
molecular
control
developmental,
physiological,
pathological
processes
within
beyond
system.
Archives of Toxicology,
Journal Year:
2021,
Volume and Issue:
95(7), P. 2279 - 2297
Published: May 18, 2021
Over
the
last
decade,
important
clinical
benefits
have
been
achieved
in
cancer
patients
by
using
drug-targeting
strategies.
Nevertheless,
drug
resistance
is
still
a
major
problem
most
therapies.
Epithelial-mesenchymal
plasticity
(EMP)
and
tumour
microenvironment
described
as
limiting
factors
for
effective
treatment
many
types.
Moreover,
epithelial-to-mesenchymal
transition
(EMT)
has
also
associated
with
therapy
different
preclinical
models,
although
limited
evidence
obtained
from
studies
samples.
In
this
review,
we
particularly
deepen
into
mechanisms
of
which
intermediate
epithelial/mesenchymal
(E/M)
states
its
interconnection
to
influence
resistance.
We
describe
how
use
bioinformatics
pharmacogenomics
will
help
figure
out
biological
impact
EMT
on
develop
novel
pharmacological
approaches
future.
